Lactobacilluscasei reduces CD8+ T cell‐mediated skin inflammation

Chapat, Ludivine; Chemin, Karine; Dubois, Bertrand; Bourdet‐Sicard, Raphaëlle; Kaiserlian, Dominique

doi:10.1002/eji.200425139

Cited by 155 publications

(119 citation statements)

References 51 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…For reduction of allergy, Matsuzaki et al (1998) reported that oral feeding of Lactobacillus casei strain Shirota effectively inhibited Immunoglobulin(Ig)E production both in vivo and in vitro. Besides stimulation of antibody production (Alvarez-Olmos and Oberhelman, 2001) and macrophage activity (Schiffrin et al, 1995), functional effects like inhibition of inflammation (Hart et al, 2003;Chapat et al, 2004), and autoimmune disorders (Gill and Guarner, 2004) were observed.…”

Section: Introductionmentioning

confidence: 99%

Physiological Characteristics and Immunomodulating Activity by Lactobacillus paracasei subsp. paracasei BFI46 Isolated from New-Born Infant Feces

Lim¹,

Kim²,

Cho³

et al. 2010

Korean Journal for Food Science of Animal Resources

View full text Add to dashboard Cite

In order to develop a new starter for fermented milk, Lactobacillus paracasei subsp. paracasei BFI46 (BFI46) obtained from new-born infant feces was investigated for physiological characteristics. Good immunomodulating activity was evident compared with commercial lactic acid bacteria starter cultures. The optimum growth temperature of BFI46 was 40 o C with 12 h required to reach pH 4.3. Testing with 13 different antibiotics revealed greatest sensitivity of BFI46 to penicillin-G and chloramphenicol, and heightened resistance to neomycin, kanamycin and polymyxin. BFI46 displayed higher esterase activities compared to 18 other enzymes, was comparatively tolerant to bile juice and able to survive at pH 2 for 3 h, and displayed high resistance against Escherichia coli and Salmonella Typhimurium with a survival rate of 57.14% and 96.36%, respectively. The results indicate that BFI46 could be an excellent starter culture for fermented milk with high level of immunomodulating activity.

show abstract

Section: Introductionmentioning

confidence: 99%

Physiological Characteristics and Immunomodulating Activity by Lactobacillus paracasei subsp. paracasei BFI46 Isolated from New-Born Infant Feces

Lim¹,

Kim²,

Cho³

et al. 2010

Korean Journal for Food Science of Animal Resources

View full text Add to dashboard Cite

show abstract

“…Probiotics could potentially reduce the incidence of VAP through various local and systemic effects that minimize colonization by more virulent species or optimize host immune defenses. These effects include reduced overgrowth of potentially pathogenic microorganisms, improved gut mucosal barrier function, reduced bacterial translocation, and toll-like receptormediated up-regulation of immune function (16)(17)(18)(19)(20)(21). Evidence supporting this theory is limited but promising (22).…”

mentioning

confidence: 99%

Probiotic Prophylaxis of Ventilator-associated Pneumonia

Morrow¹,

Kollef²,

Casale³

2010

Am J Respir Crit Care Med

321

329

View full text Add to dashboard Cite

Rationale: Enteral administration of probiotics may modify the gastrointestinal environment in a manner that preferentially favors the growth of minimally virulent species. It is unknown whether probiotic modification of the upper aerodigestive flora can reduce nosocomial infections. Objectives: To determine whether oropharyngeal and gastric administration of Lactobacillus rhamnosus GG can reduce the incidence of ventilator-associated pneumonia (VAP). Methods: We performed a prospective, randomized, double-blind, placebo-controlled trial of 146 mechanically ventilated patients at high risk of developing VAP. Patients were randomly assigned to receive enteral probiotics (n 5 68) or an inert inulin-based placebo (n 5 70) twice a day in addition to routine care. Measurements and Main Results: Patients treated with Lactobacillus were significantly less likely to develop microbiologically confirmed VAP compared with patients treated with placebo (40.0 vs. 19.1%; P 5 0.007). Although patients treated with probiotics had significantly less Clostridium difficile-associated diarrhea than patients treated with placebo (18.6 vs. 5.8%; P 5 0.02), the duration of diarrhea per episode was not different between groups (13.2 6 7.4 vs. 9.8 6 4.9 d; P 5 0.39). Patients treated with probiotics had fewer days of antibiotics prescribed for VAP (8.6 6 10.3 vs. 5.6 6 7.8 d; P 5 0.05) and for C. difficile-associated diarrhea (2.1 6 4.8 SD d vs. 0.5 6 2.3 d; P 5 0.02). No adverse events related to probiotic administration were identified. Conclusions: These pilot data suggest that L. rhamnosus GG is safe and efficacious in preventing VAP in a select, high-risk ICU population. Clinical trial registered with www.clinicaltrials.gov (NCT00613795).

show abstract

“…casei DN-114 001 were prepared at a stationary phase of growth as previously described (24). Mice (five to seven per group) were fed daily by gavage with 200 l of 10 8 CFU/ml L. casei DN 114 001 or 0.9% NaCl (control) from day 14 before colonic DNBS sensitization until the end of the experiments.…”

Section: Probiotic Treatmentmentioning

confidence: 99%

“…ϩ T cell-mediated skin contact hypersensitivity to 2,4-dinitro-1-fluorobenzene via a mechanism that required CD4 ϩ T cells (24). We thus asked whether the same L. casei treatment protocol could alleviate acute DNBS-specific CD8 colitis in BALB/c mice.…”

Section: Severity Of Cd8mentioning

confidence: 99%

CD4+ T Cells and Lactobacillus casei Control Relapsing Colitis Mediated by CD8+ T Cells

Hacini‐Rachinel

Nancey²,

Boschetti³

et al. 2009

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

Evidence that CD4+ regulatory T cells can control Ag-specific CD8+ T cell-mediated colitis in immunocompetent mice is poorly documented. To examine the potential of CD4+ T cells to control colitis, we used our model of CD8+ T cell-mediated colitis induced by intracolonic sensitization followed by challenge with the hapten 2,4-dinitrobenzene sulfonic acid. The defect of CD4+ T cells in MHC class II-deficient (Aβ°/°) mice allowed priming of 2,4-dinitrobenzene sulfonic acid-specific IFN-γ-producing CD8 colitogenic effectors and development of colitis in the otherwise resistant C57BL/6 strain. Cotransfer experiments in RAG2°/° mice and ex vivo studies showed that CD4+CD25+ T cells completely prevented CD8+ T cell-mediated colitis and controlled CD8+ T cell activation, respectively. In the susceptible BALB/c strain, Ab depletion revealed that lack of CD4+ regulatory T cells resulted in 1) acute colitis elicited by a suboptimal dose of hapten challenge and 2) more severe relapsing episodes of colitis induced by effector/memory CD8+ T cell-mediated colitis at an optimal dose of hapten challenge, even when CD4 depletion was performed just before the second challenge. Oral administration of the probiotic strain Lactobacillus casei DN-114 001 alleviated colitis and increased the suppressive function of Foxp3+CD4+ regulatory T cells of colon lamina propria. These data demonstrate that CD4+ regulatory T cells exert a protective effect on colitis by controlling colitogenic effector/memory CD8+ T cells during the effector (symptomatic) phase of acute and relapsing colitis, respectively. Probiotics with natural adjuvant effects on mucosal regulatory T cells may represent a valuable approach to alleviate the colitogenic effect of Tc1-type CD8+ effectors.

show abstract

Lactobacilluscasei reduces CD8⁺ T cell‐mediated skin inflammation

Cited by 155 publications

References 51 publications

Physiological Characteristics and Immunomodulating Activity by Lactobacillus paracasei subsp. paracasei BFI46 Isolated from New-Born Infant Feces

Physiological Characteristics and Immunomodulating Activity by Lactobacillus paracasei subsp. paracasei BFI46 Isolated from New-Born Infant Feces

Probiotic Prophylaxis of Ventilator-associated Pneumonia

CD4+ T Cells and Lactobacillus casei Control Relapsing Colitis Mediated by CD8+ T Cells

Contact Info

Product

Resources

About